Cosmo Bio Company,Limited logo

Cosmo Bio Company,Limited

3386.T

JPXHealthcareMedical - Diagnostics & Research

Latest quote

¥1,250

−¥4.00 · -0.32%

Aug 24, 1:19 PM JSTData delayed

3386.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Cosmo Bio Company, Limited is a key player in the life science research sector, involved in the global import, export, manufacturing, marketing, and distribution of essential biotools. Their extensive product line includes biochemical reagents, specialized kits, scientific instruments, analytical software, and diagnostic products. Among their research reagents, they offer a wide spectrum such as antibodies, antigens, bioactive substances, enzymes, peptides, amino acids, various chemicals, carbohydrates, lipids, and components derived from viruses and bacteria. They also provide crucial detection reagents, cell and tissue culture systems, and gene analysis solutions. In terms of instrumentation, Cosmo Bio supplies electrophoresis apparatuses, cell culture labware, gene manipulation systems, and data analysis software. Beyond products, the company delivers valuable services like drug discovery support, custom research, and clinical diagnostics. A significant part of their operation involves the development and manufacturing of proprietary cell and cell culture products. This includes a range of specialized cells such as adipose tissue, bone, cartilage, tooth, pancreas, liver function, cardiovascular, immune, and mesenchymal stem cells, in addition to feeder cells, tumor cell lines, coating reagents, and macrophage-related products. They also produce various assay kits for measurement, staining, detection, and purification. Furthermore, they offer specialized biotechnology research equipment, including constant-temperature transport containers, aluminum block heat insulation devices, and dew condensation prevention glass plates, alongside consigned services for custom peptide synthesis and antibody production. Serving a diverse clientele of laboratories, research institutes, and life science education and testing organizations, Cosmo Bio distributes its products through its own outlets in Japan and an international network of sales agents. The company was founded in Tokyo, Japan, in 1978, where its headquarters remain.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
JP
CEO
Norihiko Shibayama
Listed since
Sep 27, 2005
Employees
182

Market position

Day range

Current ¥1,250

52-week range

Current ¥1,250

Open
¥1,254
Previous close
¥1,254
Volume
700
0.15× average
Average volume
4.57K
Average daily volume
Market cap
7.09B JPY
Beta
0.17
Market reference 1
50-day average
¥1,246.66
+0.27% above average
200-day average
¥1,285.94
-2.79% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
4.69B JPY
P/E (TTM)
19.49×
P/B (TTM)
0.73×
P/S (TTM)
0.63×
EV / EBITDA
9.21×
Earnings yield
4.53%
Free cash flow yield
4.94%
Dividend yield
4.00%

Profitability & efficiency

Gross margin
34.38%
Operating margin
3.09%
Net margin
3.22%
Return on equity
3.58%
Return on assets
2.65%
Return on invested capital
2.01%

Financial health

Debt / equity
0.08×
Current ratio
5.23×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends43%29%14%-1%Gross margin, FY2021: 39.64%Gross margin, FY2022: 36.02%Gross margin, FY2023: 34.80%Gross margin, FY2024: 33.17%Gross margin, FY2025: 34.39%Operating margin, FY2021: 11.35%Operating margin, FY2022: 8.54%Operating margin, FY2023: 5.56%Operating margin, FY2024: 3.17%Operating margin, FY2025: 3.18%Net margin, FY2021: 7.98%Net margin, FY2022: 5.41%Net margin, FY2023: 4.73%Net margin, FY2024: 2.61%Net margin, FY2025: 3.12%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 39.64%. Gross margin FY2022 36.02%. Gross margin FY2023 34.80%. Gross margin FY2024 33.17%. Gross margin FY2025 34.39%. Operating margin FY2021 11.35%. Operating margin FY2022 8.54%. Operating margin FY2023 5.56%. Operating margin FY2024 3.17%. Operating margin FY2025 3.18%. Net margin FY2021 7.98%. Net margin FY2022 5.41%. Net margin FY2023 4.73%. Net margin FY2024 2.61%. Net margin FY2025 3.12%.

Income trends

Revenue

10.77B JPY+7.26%

Operating income

342M JPY+7.55%

Net income

336M JPY+28.24%
Income trends across reported periods11.82B JPY7.61B JPY3.41B JPY−788.4M JPYRevenue, FY2021: 9.23B JPYRevenue, FY2022: 9.55B JPYRevenue, FY2023: 9.34B JPYRevenue, FY2024: 10.04B JPYRevenue, FY2025: 10.77B JPYOperating income, FY2021: 1.05B JPYOperating income, FY2022: 816M JPYOperating income, FY2023: 519M JPYOperating income, FY2024: 318M JPYOperating income, FY2025: 342M JPYNet income, FY2021: 737M JPYNet income, FY2022: 517M JPYNet income, FY2023: 442M JPYNet income, FY2024: 262M JPYNet income, FY2025: 336M JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 9.23B JPY. Revenue FY2022 9.55B JPY. Revenue FY2023 9.34B JPY. Revenue FY2024 10.04B JPY. Revenue FY2025 10.77B JPY. Operating income FY2021 1.05B JPY. Operating income FY2022 816M JPY. Operating income FY2023 519M JPY. Operating income FY2024 318M JPY. Operating income FY2025 342M JPY. Net income FY2021 737M JPY. Net income FY2022 517M JPY. Net income FY2023 442M JPY. Net income FY2024 262M JPY. Net income FY2025 336M JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue10.77B JPY10.04B JPY9.34B JPY9.55B JPY9.23B JPY
Cost of goods sold7.06B JPY6.71B JPY6.09B JPY6.11B JPY5.57B JPY
Gross profit3.7B JPY3.33B JPY3.25B JPY3.44B JPY3.66B JPY
Research and development83M JPY73M JPY82M JPY70M JPY
Selling, general, and administrative3.36B JPY2.93B JPY2.73B JPY2.54B JPY2.54B JPY
Operating expenses3.36B JPY3.01B JPY2.73B JPY2.62B JPY2.61B JPY
Interest income13M JPY9M JPY6M JPY3M JPY3M JPY
Depreciation and amortization167M JPY136M JPY148M JPY141M JPY166M JPY
Operating income342M JPY318M JPY519M JPY816M JPY1.05B JPY
Net income336M JPY262M JPY442M JPY517M JPY737M JPY

Company facts updated Aug 24, 2026.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

¥50.00

2025 complete year+38.9% since 2021

2026 partial: ¥25.00

* Partial calendar year in the available dividend history.

Corporate action history

DividendUpcoming

Ex-dividend Dec 29, 2026

¥25.00

Semi-Annual

Record Dec 31, 2026 · Payment Dec 29, 2026

Dividend

Ex-dividend Jun 29, 2026

¥25.00

Semi-Annual

Record Jun 30, 2026 · Payment Sep 10, 2026

Dividend

Ex-dividend Dec 29, 2025

¥25.00

Semi-Annual

Record Dec 31, 2025 · Payment Mar 25, 2026

Dividend

Ex-dividend Jun 27, 2025

¥25.00

Semi-Annual

Record Jun 30, 2025 · Payment Sep 10, 2025

Dividend

Ex-dividend Dec 27, 2024

¥36.00

Semi-Annual

Record Dec 31, 2024 · Payment Mar 26, 2025

Dividend

Ex-dividend Jun 27, 2024

¥14.00

Semi-Annual

Record Jun 30, 2024 · Payment Sep 10, 2024

3386.T peers

Continue in GoAI

Research 3386.T

research.disclaimer